The Breast Cancer Society of Canada

Research saves lives!
Breast Cancer Ribbon

Posts Tagged ‘metastatic breast cancer’

Kathy Steffan – What’s My Breast Cancer Story?

posted by:

Kathy Steefan - BCSC

Throughout my professional career, I have been involved with many non-profilt organizations, both as a board member and as an auditor/advisor. I feel that this is my most significant board involvement because of my personal connection with breast cancer. It involves my own baby girl, Nicole. Actually, she hasn’t been a baby for a long time, except to me.

Nicole’s story starts in 2006, at age 22, when she found a painful lump on her breast. Because she was young, healthy and active, she thought it meant nothing. Over the next 2 years the pain slowly got worse, and several doctors dismissed the lump as a benign cyst, because, of course, she was too young to have cancer. Finally, she had an ultrasound in Toronto and was eventually diagnosed with stage III breast cancer. Nicole started treatment at St. Michael’s Hospital in Toronto with a plan that included surgery, chemotherapy and radiation. Within 7 months of the initial diagnosis Nicole received a clean bill of health. Her annual check-ups were good news for the following seven years.

In early 2015,  Nicole was 31 years old and living in Calgary,  pursuing a successful career in Commercial Real Estate. That Spring, she started to feel pain and discomfort in one of her ribs after any physical activity. All of her doctors, including her original oncologist in Toronto, said it was a broken rib that would need time to heal. When the pain persisted into the Fall, a doctor in Calgary ordered a CT scan. This time, Nicole had stage IV metastatic breast cancer, and it was in her lungs and her bones–which had led to her broken rib.

Nicole on her 33rd Birthday in July 2017 with her fabulous puppy Bobby.

Nicole on her 33rd Birthday in July 2017.

We had expected that she would have to endure chemo, radiation and much more. However, we were pleasantly surprised to learn that because Nicole’s breast cancer is 99% estrogen, the treatment would be three weeks of radiation, followed by ongoing hormone treatment and ovarian suppression. Three months later, all of the tumours were reduced significantly and we continued to hope.

It is now September 2017 and we all feel very fortunate that the treatment is still working. In Nicole’s case, metastatic breast cancer has become a chronic disease that can be treated, which is a huge contrast to what it was in the past. And if the current treatment becomes less effective, there are lots of options.

Notably, the treatment that Nicole is now receiving did not exist in 2009. Her outcomes would have been very different. The advancements in treatment in even the last five to 10 years have been incredible. This is the core of the reason that I am involved in the Breast Cancer Society of Canada (BCSC). Because I am convinced that the research focus and mandate of the (BCSC) will make a difference. I feel confident that my involvement will actually make a difference.

I am encouraged and excited about the hope that exists, and look forward to the future when we finally put a stop to this disease.

Like Kathy Steffan start making a difference today give to life-saving breast research. Learn more about ways you can give at


Breast cancer cell migration research

posted by:

Hello, everyone! My name is Sami Khan and I’m an MSc candidate in the Department of Anatomy and Cell Biology at Western University. I work at London Cancer Regional Program under the supervision of Dr. Alison Allan. Our lab focuses on breast cancer metastasis: the process by which cancerous cells can leave the breast and establish tumours in other organs.

Sami Khan BCSC funded Breast Cancer ResearcherOne of the most common and deadly sites of breast cancer metastasis is the lung. For my project, I am currently investigating a family of proteins produced by the normal lung called selectins, and how they may play a role in helping breast cancer cells spread to and grow in the lung as metastatic tumours. To date, we have promising results that suggest selectins are involved in the migration (movement) of breast cancer cells and we are now investigating the mechanism by which this happens. Successful identification of a common mechanism by which the different selectins act will provide a new potential therapeutic target in limiting the spread of breast cancer to and from the lung.

This April, I had the opportunity to present my research at the 108th Annual Meeting of the American Association of Cancer Research in Washington, D.C. With over 20,000 attendees at the conference, it was an amazing opportunity to interact with scientists and clinicians from around the world, and learn about the breadth of research being conducted in the field. Returning to the lab with my newfound knowledge and expert advice, I am excited to see what we can accomplish next in our goal towards curing breast cancer.

Thank you to BCSC for your trainee support!

Sami Khan, MSc Candidate

Pamela Greenaway-Kohlmeier Translational Breast Cancer Research Unit, London Health Sciences Centre

How do breast cancer cells move through the body?

posted by:
Drs. Desnoyer and Lewis

Drs. Desnoyer and Lewis at the Atlantic Cancer Research Institute in Moncton, NB

Drs. Desnoyers and Lewis are working to understand how breast cancer cells can move throughout the body. Breast cancer becomes more aggressive when normal breast cells change to become invasive by a process called epithelial-to-mesenchymal transition (EMT). Following EMT, breast cancer cells can move throughout the body and spread the tumor, an event known as metastasis. In recent years, small molecules called miRNA have been shown to be important in the regulation of EMT and the formation of metastases. Given that miRNAs are fairly easy to detect from biological fluids, they are currently employed as cancer biomarkers.

Drs. Desnoyers and Lewis want to characterize the way these miRNAs contribute to EMT to provide a better understanding of how breast cancer metastasis is regulated, with the goal of identifying novel miRNAs involved in the regulation of EMT and breast cancer metastasis.

Through their research, Drs. Desnoyers and Lewis hope to gain a better understanding of EMT and the metastatic process, which may lead to the identification of novel therapeutic targets for the treatment of metastatic breast cancer. In addition, the novel miRNAs that they identify in their study could be suitable biomarkers to help in the early detection of metastatic breast cancer.


Dr. Guillaume Desnoyers and Dr. Stephen Lewis at the Atlantic Cancer Research Institute in Moncton, New Brunswick received funding from the Breast Cancer Society of Canada through a partnership with the QEll Foundation and the Beatrice Hunter Cancer Research Institute.